Humedica, a Boston-based clinical informatics company, has raised $20 million in a round of equity financing, according to an SEC filing. The firm, which previously raised $30 million from Bain Capital Ventures, General Catalyst Partners, North Bridge Venture Partners, and the investment bank Leerink Swann in summer 2008, came out of stealth mode in September 2009. According to its SEC filing for this latest round, all of the company’s previous backers are represented on its board of directors. Paul Bleicher, who is listed as a director of the company, was founding CEO and chairman of Phase Forward, the Waltham, MA-based provider of clinical trials software that tech giant Oracle (NASDAQ:[[ticker:ORCL]]) bought last year in a deal valued at $685 million.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
